Tirzepatide and Pregnancy Category: The Clear Guidance

The misconception worth correcting first: there is no 'safe' pregnancy category rating for tirzepatide

Many people arrive at this question expecting a letter grade (Category A, B, C) because that classification system is familiar from US prescribing. The UK does not use that framework. What the UK does have is the Mounjaro Summary of Product Characteristics, and it is straightforward: tirzepatide should not be used during pregnancy. That guidance is not a gap in the evidence waiting to be filled with reassurance. It reflects findings from animal reproductive toxicity studies that showed adverse effects on foetal development, combined with a complete absence of controlled human pregnancy data. When the data does not exist to confirm safety, the clinical position is clear.

A question our prescribers hear most weeks is whether tirzepatide being a 'natural' gut hormone means it is less risky in pregnancy. The answer is no. GLP-1 receptor agonists slow gastric emptying, affect insulin signalling and act on pathways involved in foetal development, and you can read more about how tirzepatide affects pregnancy at a physiological level for a fuller explanation of why the mechanism that makes it effective for weight management is precisely the reason caution is warranted. You can read the NHS patient information for tirzepatide for a plain-English overview of the medicine's profile, including its use restrictions.

If you are currently taking tirzepatide and have just discovered you are pregnant, our dedicated page for people who find themselves pregnant while on tirzepatide explains what to do immediately, and the short answer is to stop the medicine and speak to your GP or midwife the same day. That is not a reason to panic, it is the right next step, and your clinical team will guide you from there.

Contraception while on tirzepatide: the practical detail that often gets missed

Because tirzepatide slows gastric emptying, it can affect how quickly oral medicines are absorbed, and that includes the contraceptive pill. The Mounjaro prescribing guidance recommends that women using oral contraceptives add a non-oral method, such as condoms, for the first four weeks of treatment and for four weeks after every dose increase. After that, if your oral contraceptive is working normally and you are not changing dose, the additional precaution is no longer specified, but if you have any doubt, speak to your prescriber or GP.

NHS England's guidance on weight-management injections covers this contraception interaction and also notes that for women using HRT, transdermal preparations (patches or gels rather than tablets) are worth discussing with a doctor for the same absorption reason. These are practical, solvable issues, but they need to be on your radar from day one of treatment.

For anyone considering tirzepatide who is not currently using contraception and is sexually active, this is a conversation to have before starting. Our page on Mounjaro and pregnancy covers the contraception question in more detail, including the wash-out period guidance for people planning to conceive.

What happens if you want to start a family while on tirzepatide

Tirzepatide is not a permanent commitment, and stopping it when you want to become pregnant is entirely expected. The question is timing. The medicine has a half-life that means it clears the body over several weeks, and current guidance recommends a wash-out period before trying to conceive, your prescriber will give you the specific timeframe based on which dose you are on and the most current recommendations at the time. Do not try to work this out from the internet; the guidance can be updated and your dose matters.

Weight management during pregnancy is best discussed with your midwife or GP, who can advise on appropriate nutrition and activity. Some people worry that stopping tirzepatide will immediately reverse their progress. Weight regain can happen after stopping any GLP-1 medicine, but the answer to that concern is a plan made with a clinician before you stop, not continuing a medicine contraindicated in pregnancy. There is more on what to expect after stopping, including the lifestyle and dietary support that can help maintain progress.

If you are not yet pregnant but want to understand your options now, checking your eligibility through a free consultation gives you the space to ask exactly these questions before committing to anything.

Breastfeeding, post-natal weight, and when tirzepatide might eventually be considered

Tirzepatide is not recommended while breastfeeding. It is not known whether tirzepatide passes into human breast milk, and the risk to a nursing infant cannot be excluded. The SmPC is explicit: use during breastfeeding should be avoided. This applies even if you feel well and your baby is thriving, the absence of visible harm is not the same as confirmed safety.

Post-natal weight management is a genuine clinical need, and one that is sometimes dismissed or rushed. Once breastfeeding has ended and a clinician is satisfied the wash-out considerations have been addressed, tirzepatide may be reconsidered for eligible adults. That assessment takes into account BMI, any weight-related conditions and your overall health picture, the same thorough review that applies to any new patient. Our page covering Mounjaro and pregnancy addresses the post-natal period in more detail, including when it may be appropriate to revisit treatment.

For context on the broader treatment landscape after the post-natal period, our weight-loss treatment overview sets out the options that may be available, and our clinical team is there to answer questions that fall outside a short FAQ. If you have something specific to ask in the meantime, our support team is available seven days a week.